Perrigo Company announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal(R) tablets, from Synthon Pharmaceuticals, Inc. Synthon believes it has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Synthon and UCB are currently engaged in Paragraph IV/Hatch-Waxman litigation over the Synthon ANDA filing.
The details can be read here.
No comments:
Post a Comment